Compare PAR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | HRMY |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.7M | 1.6B |
| IPO Year | 1995 | 2020 |
| Metric | PAR | HRMY |
|---|---|---|
| Price | $12.81 | $26.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $34.20 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 2.3M | 644.8K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | $455,547,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $9.82 | $19.75 |
| Revenue Next Year | $11.27 | $12.88 |
| P/E Ratio | ★ N/A | $10.12 |
| Revenue Growth | ★ 30.16 | 21.51 |
| 52 Week Low | $12.47 | $25.52 |
| 52 Week High | $72.15 | $40.87 |
| Indicator | PAR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 30.74 |
| Support Level | $12.47 | $25.71 |
| Resistance Level | $38.02 | $28.99 |
| Average True Range (ATR) | 1.01 | 0.69 |
| MACD | 0.14 | 0.18 |
| Stochastic Oscillator | 8.94 | 0.43 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.